I don't care why it's going up. By the way, how much do the hedge funds pay you? Maybe I should look into that for some side money...
Adam Lasher could go deep into the American Idol finals. If he brings attention to his Type 1 diabetes and Afrezza, we could get a spike in interest.
$20 per share/$9B EV implies probably 300-400,000 user potential worldwide assuming $900m in annual sales and 10X EV/sales. Before I made a bid, I'd like to see half of that number, or 150-200k users. Right now, we're about 7k users. So in my opinion, a bid Al can live with is a year or more away, assuming we don't go BK first. Look, it's a long-shot. Don't expect too much/too soon and you won't be disappointed.
It is worth paying attention to. If we move up 20% per week, in four months we're doing 5000 per week and any rapid increase will juice the stock price and we can do a secondary.
It's half the market size of US. Any idea if Mexico accepts FDA approval under NAFTA or does it require a long certification process? I know for devices it's less than 60 days, but Afrezza is a drug, too. Thanks.
On the CC, Matt said two study results would be unveiled at this conference. Is one of them the so-called superiority study? Because to me, that's what's been holding Afrezza back, namely the idea that it isn't better than existing insulins. If they can show superiority to Humalog, I think scripts are going to go way up. My 2 cents.
This was reported on in the media recently. JnJ didn't waste any time teaming up with that group. I believe the research was done at Harvard. Still, it's only been done in mice and it will take up to a decade if it works at all. Lots of money to be made between now and nirvana.
Has anyone crunched the numbers? If so, please post. Thanks.
Look, if MNKD gets back to $3 they can sell 20-30 million shares and live another 6-9 months at current cash burn. It wouldn't take much to get us back to $3. A couple of good weekly script numbers and we're there.
His Youtube videos for Afrezza are highly effective. Eric is a Type 1 diabetic on Afrezza and he interviews other Type 1's on Afrezza telling their success stories. He could begin every commercial with: "This is Eric Fenar for Afrezza..." Check them out if you haven't seen them yet. Afrezza is a new kind of insulin and needs a new kind of advertising to promote it.
With all due respect, if MNKD could sell Afrezza for a billion dollars and a 20% royalty, we wouldn't be under a buck.
If oil goes below $20, it won't stay there. Look at the futures curve. December last checked was $40, and that was before the run of the past few days.